Summary
The metabolic effects of cyproterone acetate (2 mg) combined with a new dose level
of ethinyl estradiol (35 μg) were studied over a one-year period in 31 patients presenting
moderate clinical hyperandrogenism. The following tests were performed before treatment,
at 6 and 12 months, an oral glucose tolerance test (OGTT) with measurement of insulinemia,
total cholesterol, HDL cholesterol and the LDL + VLDL/ratio HDL, A1 and B apoproteins. At six months and at one year of treatment, the weight and body
mass index (kg/m2) were not modified. Glucose tolerance and insulinemia had not changed significantly
at one year. Lipid test results showed an increase in triglycerides, as well as in
total and HDL cholesterol levels. However, the LDL + VLDL/HDL and A1/B apoprotein ratios did not change during the study. We conclude from these results
that the new combination does not have any adverse effects on glucose tolerance and
has a predominantly estrogenic effect on lipid parameters, characterized by increases
in total cholesterol, HDL cholesterol and triglycerides.
Key words
Cyproterone Acetate - Ethinyl Estradiol - Oral Glucose Tolerance Test - Total Cholesterol
- HDL Cholesterol - Triglycerides - Apoproteins